In a significant advancement for heart health management, Esperion (NASDAQ: ESPR) has announced that the United States Food and Drug Administration (FDA) has approved comprehensive label expansions for its flagship products, NEXLETOL (bempedoic acid) Tablets and NEXLIZET (bempedoic acid and ezetimibe) Tablets. This approval, rooted in the positive data from the CLEAR Outcomes trial, heralds […]
The U.S. Food and Drug Administration (FDA) has recently granted an additional indication for Novo Nordisk’s Wegovy, a milestone in medical advancements aimed at combating cardiovascular diseases (CVD). This new approval positions Wegovy as the first treatment option specifically approved to reduce the risk of major cardiovascular events such as death, heart attack, or stroke […]
